<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><submitter>Riordan R</submitter><funding>BLRD VA</funding><funding>NIA NIH HHS</funding><funding>NINDS NIH HHS</funding><funding>NIH HHS</funding><pubmed_abstract>Genetic variation in the lysosomal and transmembrane protein 106B (TMEM106B) modifies risk for a diverse range of neurodegenerative disorders, especially frontotemporal lobar degeneration (FTLD) with progranulin (PGRN) haplo-insufficiency, although the molecular mechanisms involved are not yet understood. Through advances in cryo-electron microscopy (cryo-EM), homotypic aggregates of the C-Terminal domain of TMEM106B (TMEM CT) were discovered as a previously unidentified cytosolic proteinopathy in the brains of FTLD, Alzheimer's disease, progressive supranuclear palsy (PSP), and dementia with Lewy bodies (DLB) patients. While it remains unknown what role TMEM CT aggregation plays in neuronal loss, its presence across a range of aging related dementia disorders indicates involvement in mult</pubmed_abstract><journal>bioRxiv : the preprint server for biology</journal><pagination>2024.06.11.598478</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11195232</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>TMEM106B C-terminal fragments aggregate and drive neurodegenerative proteinopathy.</pubmed_title><pmcid>PMC11195232</pmcid><funding_grant_id>I01 BX004044</funding_grant_id><funding_grant_id>R01 AG066729</funding_grant_id><funding_grant_id>P40 OD010440</funding_grant_id><funding_grant_id>R01 NS064131</funding_grant_id><funding_grant_id>IK6 BX006467</funding_grant_id><pubmed_authors>Saxton A</pubmed_authors><pubmed_authors>Liachko NF</pubmed_authors><pubmed_authors>Kow RL</pubmed_authors><pubmed_authors>Kraemer BC</pubmed_authors><pubmed_authors>Riordan R</pubmed_authors><pubmed_authors>McMillan PJ</pubmed_authors></additional><is_claimable>false</is_claimable><name>TMEM106B C-terminal fragments aggregate and drive neurodegenerative proteinopathy.</name><description>Genetic variation in the lysosomal and transmembrane protein 106B (TMEM106B) modifies risk for a diverse range of neurodegenerative disorders, especially frontotemporal lobar degeneration (FTLD) with progranulin (PGRN) haplo-insufficiency, although the molecular mechanisms involved are not yet understood. Through advances in cryo-electron microscopy (cryo-EM), homotypic aggregates of the C-Terminal domain of TMEM106B (TMEM CT) were discovered as a previously unidentified cytosolic proteinopathy in the brains of FTLD, Alzheimer's disease, progressive supranuclear palsy (PSP), and dementia with Lewy bodies (DLB) patients. While it remains unknown what role TMEM CT aggregation plays in neuronal loss, its presence across a range of aging related dementia disorders indicates involvement in mult</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 Jun</publication><modification>2025-09-01T03:16:40.524Z</modification><creation>2025-09-01T03:08:29.942Z</creation></dates><accession>S-EPMC11195232</accession><cross_references><pubmed>38915598</pubmed><doi>10.1101/2024.06.11.598478</doi></cross_references></HashMap>